Evidence map›Paper›PMID 38134199›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants.

Zhongfeng Ye, Srinivasa Reddy Bonam, Lindsay G A McKay, Jessica A Plante, Jordyn Walker, Yu Zhao, Changfeng Huang, Jinjin Chen, Chutian Xu, Yamin Li and 10 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Designing 5' UTR sequences improves the capacity of mRNA therapeutics in preclinical models of aging and obesity.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Molecular therapy. Nucleic acids · 2025
    Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Zhongfeng Ye *Department of Biomedical Engineering, Tufts University, Medford, MA 02155.ORCID 0000-0003-0383-7247
Srinivasa Reddy Bonam *Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.ORCID 0000-0002-2888-2418
Lindsay G A McKayNational Emerging Infectious Diseases Laboratories and Department of Virology, Immunology, and Microbiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02215.ORCID 0000-0003-0369-9067
Jessica A PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.ORCID 0000-0002-4768-7458
Jordyn WalkerDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.
Yu ZhaoDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155.
Changfeng HuangDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155.
Jinjin ChenDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155.
Chutian XuDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155.
Yamin LiDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210.ORCID 0000-0002-5535-1807
Lihan LiuDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155.
Joseph HarmonDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155.ORCID 0000-0002-6445-2191
Shuliang GaoDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155.
Donghui SongDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155.ORCID 0000-0001-9081-4275
Zhibo ZhangDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155.ORCID 0009-0007-7320-3983
Kenneth S PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.ORCID 0000-0002-7485-3167
Anthony GriffithsNational Emerging Infectious Diseases Laboratories and Department of Virology, Immunology, and Microbiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02215.ORCID 0000-0001-5435-8364
Jianzhu ChenKoch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139.ORCID 0000-0002-5687-6154
Haitao HuDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.
Qiaobing XuDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155.
Tufts University · USThe University of Texas Medical Branch at Galveston · USBoston University · USSUNY Upstate Medical University · US

Funding

World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5M
NIAID NIH HHS R24 AI120942
6 · The paper itself

Abstract

The emergence of highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that are resistant to the current COVID-19 vaccines highlights the need for continued development of broadly protective vaccines for the future. Here, we developed two messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccines, TU88mCSA and ALCmCSA, using the ancestral SARS-CoV-2 spike sequence, optimized 5' and 3' untranslated regions (UTRs), and LNP combinations. Our data showed that these nanocomplexes effectively activate CD4

Indexed as

COVID-19COVID-19 Vaccines3' Untranslated RegionsAnimalsAntibodies, NeutralizingAntibodies, ViralCricetinaeHumansMicemRNA VaccinesRNA, MessengerSARS-CoV-23' Untranslated RegionsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesmRNA VaccinesRNA, Messengerlipid nanoparticlelung tissue-resident memory T cellsmRNA vaccineuntranslated region

Identifiers

PMID38134199
PMCPMC10756290
OpenAlexW4390100433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.